GenMark Diagnostics, Inc  

(Public, NASDAQ:GNMK)   Watch this stock  
Find more results for GNMK
15.20
-0.09 (-0.59%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.98 - 15.32
52 week 4.01 - 16.00
Open 15.28
Vol / Avg. 92,990.00/151,570.00
Mkt cap 497.85M
P/E     -
Div/yield     -
EPS -1.00
Shares 32.75M
Beta     -
Inst. own 78%
Aug 7, 2013
Q2 2013 GENMARK DIAGNOSTICS INC Earnings Release Add to calendar
May 15, 2013
GENMARK DIAGNOSTICS INC at Bank of America Merrill Lynch Health Care Conference
May 8, 2013
Q1 2013 GENMARK DIAGNOSTICS INC Earnings Conference Call
May 8, 2013
Q1 2013 GENMARK DIAGNOSTICS INC Earnings Release
Mar 12, 2013
Q4 2012 GENMARK DIAGNOSTICS INC Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -49.70% -107.98%
Operating margin -48.66% -106.95%
EBITD margin - -100.12%
Return on average assets -27.55% -41.62%
Return on average equity -32.30% -50.76%
Employees 130 -
Carbon Disclosure Rating - -

Address

5964 La Place Court, Suite 100
CARLSBAD, CA 92008
United States - Map
+1-760-4484300 (Phone)
+1-760-4484301 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology. The Company�s electrochemical technology enables detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA), and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its eSensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.

Officers and directors

Christopher M. Gleeson Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Hany Massarany President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Richard B. Slansky Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Matthew R. Cohen Senior Vice President, General Counsel, Corporate Secretary
Age: 40
Bio & Compensation  - Reuters
Michael Gleeson Senior Vice President - Sales
Age: 37
Bio & Compensation  - Reuters
Jeffrey Hawkins Senior Vice President - Marketing and Business Development
Age: 34
Bio & Compensation  - Reuters
Jennifer Williams Senior Vice President - Global Operations & Human Resources
Age: 39
Bio & Compensation  - Reuters
Jorge A. Garces Ph.D. Senior Vice President - Research and Development
Age: 40
Bio & Compensation  - Reuters
Jon Faiz Kayyem Ph.D. Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Daryl Jay Faulkner Independent Director
Age: 63
Bio & Compensation  - Reuters